LDH as a Biochemical Biomarker to Predict Organ Failure in the Emergency Department Setting
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01937676|
Recruitment Status : Completed
First Posted : September 9, 2013
Last Update Posted : September 7, 2016
|Condition or disease|
|Multiple Organ Failure|
|Study Type :||Observational|
|Actual Enrollment :||1250 participants|
|Official Title:||LDH as a Biochemical Biomarker to Predict Organ Failure in the Emergency Department Setting|
|Study Start Date :||September 2013|
|Actual Primary Completion Date :||April 2014|
Adults admitted to ER
All adult patients admitted to emergency department during the study period.
- Development of multiple organ failure [ Time Frame: 30 days or complete ICU stay ]Measured as SOFA score.
- Cardiac function [ Time Frame: 30 days or complete ICU stay ]Is it possible to predict cardiac function with the novel biomarker K3, which consists of lactate dehydrogenase, albumin, and magnesium combined?
- All cause mortality [ Time Frame: 30 days after admission to emergency department ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01937676
|Karlstad Central Hospital|
|Principal Investigator:||Mathias Karlsson, MD, PhD||Karolinska|
|Study Director:||Jan Wernerman, MD, Prof||Karolinska|
|Study Director:||Lars Wiklund, MD, Prof||Uppsala University|